Skip to content
etf.net

Launched · SEC filings

Tema Oncology ETF

CANCNasdaqD

$39.26−1.32 (−3.25%)

At close: Oct 13, 2026, 4:00 PM

D30/ 100

Rank 17 of 17 in Biotech & Genomics

D30/100Rank 17 of 17inBiotech & Genomics
Intraday session: down, 75 prints from 40.58 to 39.26. Range 39.26 to 40.54. Use the arrow keys to read each point.39.5039.7540.0040.2510 AM12 PM2 PM4 PM
Expense ratio
0.99%
Fund size
$205M
1Y total return
+37.4%
Yield · Last 12 months
0.05%
Holdings
58
Avg volume · 30D
0M sh
NAV per share
$40.77
52W range
low $29.28high $47.00
Launched
Filings
SEC EDGAR

The ETF.net CANC Grade

Based on 5 of 6 pillars

D

Score 30 out of 100

Category
Biotech & Genomics⁠
Rank
17 of 17
Six-pillar profile for CANC. Scores out of 100: Cost 0, Risk 55, Mission not scored, Tradability 36, Holdings 71, Durability 41. Strongest: Holdings (71). Weakest: Cost (0). Based on 5 of 6 pillars.

Score 30 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    F0 out of 100
    Rank 17 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B55 out of 100
    Rank 9 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D36 out of 100
    Rank 11 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    A71 out of 100
    Rank 5 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    C41 out of 100
    Rank 12 of 17

Our read on CANC

ETF.net Research

DMost health care ETFs hand you the whole hospital: insurers, devices, dental supply. CANC goes straight at cancer, holding companies that draw at least half their revenue from oncology. A narrow, single-disease portfolio, launched in 2023.

Stated mandate

The Fund seeks long-term growth. Its principal strategy invests at least 80% of net assets in publicly listed companies deriving at least 50% of revenue from oncology.

Why people hold it

  1. 01The mandate is strict, not thematic window dressing: at least 80% of net assets in listed companies earning 50%+ of revenue from oncology.
  2. 02About 60 names, so each position carries real weight instead of cancer exposure getting diluted inside a 400-stock sector basket.
  3. 03A rare pure-play: the top-scoring funds in its health care cohort (VHT, FHLC, XLV) are broad sector baskets, not disease-specific portfolios.

Worth knowing

  1. 01Specialization costs: 0.99% a year, while broad health care index funds like VHT and XLV charge single-digit basis points.
  2. 02Thinly traded next to the category's giants, so the spread you pay entering and exiting can matter as much as the expense ratio.
  3. 03One disease, roughly 60 stocks. This is a slice of health care, not the sector, and it pays out at most a couple of times a year.

CANC Holdings

As of Oct 13, 2026
Asset class
Stocks
Holdings
58
Top-10 weight
41%
Largest holding
RVMD5.5%

Sectors

  • Health Care100.0%

Geography

  • United States80.13%
  • Switzerland10.01%
  • Denmark3.76%
  • United Kingdom3.00%
  • China1.88%
  • Singapore0.71%
  • Germany0.51%
The fund’s holdings, weight-ordered — page 1 of 4.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001RVMDRevolution Medicines Inc5.54%58,135$11M176
002MRKMerck & Co Inc5.28%73,810$11M515
003LLYEli Lilly & Co4.67%8,027$9M583
004COGTCogent Biosciences Inc4.55%310,536$9M84
005NOVN.SWNovartis AG3.82%54,070$8M185
006GMABGenmab A/S3.74%203,743$8M28
007ABBVAbbVie Inc3.68%26,609$7M522
008ONCBeone Medicines Ltd3.46%20,086$7M36
009IOVAIovance Biotherapeutics Inc3.38%472,166$7M91
010EXELExelixis Inc3.28%111,710$7M244
011HALOHalozyme Therapeutics Inc3.23%59,078$7M208
012BMYBristol-Myers Squibb Co3.04%107,353$6M463
013BBIOBridgebio Pharma Inc2.72%84,251$6M119
014RHHBYRoche Holding AG2.68%100,715$5M20
015IDYAIdeaya Biosciences Inc2.60%146,636$5M92

Showing 1–15 of 58 holdings

CANC Performance

Launched Aug 14, 2023

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.
CANC$13,735
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. CANC $13,735. SPY $12,044. Use the arrow keys to read each point.$9,322$12,539$15,757Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for CANC. Periods over one year show the average yearly return.
PeriodCANC
Year to date+16.9%
1 month−2.3%
3 months−2.6%
1 year+37.4%
3 yearsper year+22.9%
5 yearsFund is under 5 years oldper year—
10 yearsFund is under 10 years oldper year—

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for CANC
YearReturn barCANC
2026 YTD+16.9%
2025+42.9%
2024−5.4%
2023+8.5%

History from Aug 17, 2023

CANC in the news

Filtered to CANC · Biotech & Genomics

CANC Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
0.05%Last 12 months
Payout per share
$0.02Last 12 months
Last payment
$0.02 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2023–2026

One bar per payment. 3 payments from 2023 to 2026 YTD. Dec 13, 2023 $0.15; Dec 11, 2024 $0.73; Dec 10, 2025 $0.02. Use the arrow keys to read each point.2023202420252026YTD
Ex-datePay dateAmount per share
Dec 10, 2025Dec 11, 2025$0.02
Dec 11, 2024Dec 12, 2024$0.73
Dec 13, 2023Dec 15, 2023$0.15

CANC Risk

How much the fund’s monthly returns vary, scaled to a year.
19.2%
Annualised · 36 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.96
vs 3-month T-bills · to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−28.0%
37 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.72
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

CANC Cost

Expense ratio0.99%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

Every other Biotech & Genomics fund charges less.

CANC costs $99.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.

Other funds in Biotech & Genomics

See others